🦊/Companies

Vitae Industries

Techstars '17

Providence, US · Founded 2014 · Delaware corporation · 3 employees on LinkedIn · 4 known investors

Find your way into Vitae Industries

906 people in our graph share verified history with the Vitae Industries team — schools, employers, funds. One of them is your warm intro.

Crystal Huangunlockedknows Jeanine Sinanan-Singh · together at Harvard University (overlapped)
knows the team · via MIT Sloan School of Management
×4knows the team · via Techstars
×2knows the team · via Harvard University
×4knows the team · via Massachusetts General Hospital

BetteRx (formerly Vitae Industries) builds the AutoCompounder, an automated dosage-making system with a vetted compound formulary that helps 503A compounding pharmacists produce personalized medications more consistently and in line with FDA regulations. It serves compounding pharmacies in the US, with installations across the country.

Also known as BetteRx · BetteRx Compounding Inc. · Vitae Industries

Founders & leadership

Vitae Industries was founded in 2014 by Jeanine Sinanan-Singh, Daniel DeCiccio, and Anthony Marsella.

JS
Jeanine Sinanan-SinghinCo-Founder & CEO2016–2023Jeanine Sinanan-Singh founded Vitae Industries (now BetteRx), which develops automated dosage-making systems for compounding pharmacies. She has experience leading products and teams through complex regulatory environments, including work with frontier AI models.
DDDaniel DeCiccio
Daniel DeCiccioinCo-Founder2015–2023
AMAnthony Marsella
Anthony MarsellainFounder & CEOAnthony Marsella is founder and CEO of BetteRx (formerly Vitae Industries), which makes the AutoCompounder, an automated system for compounding pharmacies. He previously worked in boxing management and promotion, and has experience in private equity and venture capital investments.
SJStuart Jamieson
Stuart JamiesonCFO

Investors · 4

Reported raises · per SEC filings

Form D private placements

$2.5M disclosed across 3 rounds · 2016–2017

$2.3MraisedAug 2017 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeanine Sinanan-SinghExecutive Officer, Director
  • Daniel DeCiccioExecutive Officer, Director
Offering amount
$2.3M
Amount sold
$2.3M
Minimum investment
$25.5K
First sale
Aug 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$200KraisedJan 2017 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeanine Sinanan-SinghExecutive Officer, Director
  • Daniel DeCiccioExecutive Officer, Director
Offering amount
$750K
Amount sold
$200K
Minimum investment
$25K
First sale
Jan 2017
Incorporated
Corporation, Rhode Island, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$20KraisedDec 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeanine Sinanan-SinghExecutive Officer, Director
  • Daniel DeCiccioExecutive Officer, Director
Offering amount
$20K
Amount sold
$20K
First sale
Nov 2016
Incorporated
Corporation, Rhode Island, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Company profile

researched Aug 2026

BetteRx Compounding Inc., formerly Vitae Industries, develops automation technology for pharmacy compounding. Its AutoCompounder system produces personalized medication doses through a three-step workflow: the pharmacist mixes the active pharmaceutical ingredient (API) with dosage-form-specific inactive ingredients according to the company's vetted formulas, fills a proprietary cartridge with the compound and clips it into the AutoCompounder, then enters the drug, strength(s) and quantity for the machine to dispense doses unattended.

The company positions its system as aligned with FDA regulations and the requirements of the Drug Quality and Security Act, legislation enacted following the New England Compounding Center meningitis outbreak. Its stated goal is to make personalized, compounded medication safer and as scalable and accessible as generic drugs by equipping 503A compounding pharmacists with automated dispensing technology.

Business model

The company supplies compounding pharmacies with the AutoCompounder system, proprietary cartridges and an associated vetted compound formulary.

Traction

The company reports its system in more than 28 pharmacy installations nationwide, a compound formulary of over 300 APIs, and more than 500,000 doses dispensed by the AutoCompounder.

Latest developments

BetteRx Compounding Inc. now operates the business under the BetteRx name, stating on its website that it acquired Vitae Industries' technology, and reports over 28 pharmacy installations and more than 500,000 doses dispensed.

Full profile — market position, technology, go-to-market, geography, history

Market position

The company describes itself as focused on automating personalized compounded medication production for 503A pharmacies, with its system installed in over 28 pharmacies nationwide.

Technology

The core product is the AutoCompounder, a cartridge-based automated dosage-dispensing machine paired with a compound formulary. The pharmacist prepares a compound from an API and dosage-form-specific inactive ingredients using the company's vetted formulas, loads it into a cartridge, and enters the drug, strengths and quantity; the system then dispenses the doses. The formulary covers more than 300 compound APIs.

Go-to-market

503A compounding pharmacies in the United States and the compounding pharmacists working in them.

Geography

United States; the company describes installations in pharmacies nationwide.

History

The business operated as Vitae Industries before becoming BetteRx Compounding Inc.; the company's site states that BetteRx acquired Vitae Industries' technology.

Compiled by commissioned research from 11 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
Annual revenue rangeAug 2024$5M-$20M
AutoCompounder dispensed dosesJan 2025500,000 doses
Compound formulary APIsJan 2025300 APIs
Doses dispensed by AutoCompounderJan 2025500,000 doses
Employee count rangeAug 202411-50 employees
Pharmacy installationsJan 202528 installations

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Competitors · 2

by search overlap

Companies competing with Vitae Industries for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$149.2K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Timeline · 1

launches, deals, and filings
Jan 2025
BetteRx acquired Vitae Industries' technology

The company's website states that BetteRx acquired Vitae Industries' technology and that BetteRx Compounding Inc. was formerly Vitae Industries.

source ↗

Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.

Legal entities · 1

corporate structure
Vitae IndustriesDelaware

In the news

Research sources · 11

primary sources listed

11 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Vitae Industries do?
BetteRx, formerly Vitae Industries, makes the AutoCompounder, an automated dosage-making system for 503A compounding pharmacies.
Who founded Vitae Industries?
Vitae Industries was founded by Jeanine Sinanan-Singh, Daniel DeCiccio, Anthony Marsella in 2014.
Who are Vitae Industries's investors?
Vitae Industries's investors include Compound, Slater Technology Fund, Social Starts, Techstars.
How much funding has Vitae Industries raised?
Vitae Industries has disclosed $2.5M raised across 3 rounds.
Where is Vitae Industries headquartered?
Vitae Industries is headquartered in Providence, US.